GlassScriptPhysician profile
Emily K Ricci
NPI 1740496835
$2,035.89
in general payments reported to CMS, 2019-2025
26 companies · $417 in 2025
The $417 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $94.81 · 2021: $234 · 2022: $265 · 2023: $377 · 2024: $408 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.19 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $475.03 | 2022-2025 | Veozah |
| Abbvie INC. | $426.28 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $257.78 | 2023-2025 | |
| Pfizer INC. | $112.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $86.78 | 2019-2024 | Aptima |
| Merck Sharp & Dohme LLC | $78.79 | 2019-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $75.00 | 2021-2025 | |
| Exeltis, USA INC. | $68.42 | 2019-2022 | |
| Therapeuticsmd, INC. | $64.88 | 2019-2021 | |
| Allergan, INC. | $50.94 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $47.97 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $35.75 | 2024 | |
| Millicent US INC | $30.64 | 2025 | Intrarosa, Femlyv |
| Evofem Biosciences, INC. | $29.09 | 2021-2025 | Phexxi, Solosec, Phexx |
| Renovia INC | $25.03 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $21.11 | 2024 | Paragard T 380a |
| Si-Bone, INC. | $20.27 | 2025 | |
| Organon LLC | $18.55 | 2024 | |
| Amag Pharmaceuticals, INC. | $16.05 | 2019 | |
| Axonics, INC. | $14.83 | 2024 | Axonics, Bulkamid |
| Mylan Pharmaceuticals INC. | $14.44 | 2022 | |
| Medicem INC. | $14.43 | 2021 | |
| Amgen INC. | $14.04 | 2025 | Evenity, Prolia |
| Covidien LP | $12.55 | 2019 | |
| Scynexis, INC. | $12.16 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ricci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.